中西医结合在免疫性肝病合并胃炎的临床效果及安全性

Clinical efficacy and safety of integrated traditional Chinese and Western medicine in elderly autoimmune liver disease patients with gastritis

目的探讨中西医结合在老年自身免疫性肝病合并胃炎患者中的临床效果及安全性.方法取2010-01/2016-06医院收治老年自身免疫性肝病合并胃炎患者56例,随机数字法分为对照组(n=28)和观察组(n=28).对照组采用西医对症支持治疗,观察组在对照组基础上联合中医汤药治疗,比较2组临床疗效及安全性.结果 2组治疗前谷丙转氨酶(alanine transaminase,ALT)、谷氨酰转肽酶(glutamyl transpeptidase,GGT)水平比较差异无统计学意义(P>0.05);观察组治疗后与对照组相比,ALT水平(45.31IU/L±10.04 IU/L vs 68.42 IU/L±11.46IU/L)、GGT水平(41.46 IU/L±10.24 IU/L vs 52.17 IU/L±11.25 IU/L),均低于对照组(P<0.05);2组不良反应发生率比较差异无统计学意义(P>0.05).结论老年自身免疫性肝病合并胃炎患者在西医对症支持治疗基础上联合中医汤药治疗效果理想,有助于改善患者肝功能,并且药物安全性较高,值得推广应用.

AIM To evaluate the clinical efficacy and safety of integrated traditional Chinese and Western medicine in elderly autoimmune liver disease patients with gastritis.METHODS From January 2010 to June 2016, 56 elderly autoimmune liver disease patients with gastritis were randomly divided into a control group（n = 28） and an observation group（n = 28）. Both groups were treated by Western medicine symptomatic support, and the observation group was additionally given Chinese medicine decoction. The clinical efficacy and safety of the two groups were compared.RESULTS Before treatment, there was no significant difference in alanine transaminase（ALT） or glutamyl transpeptidase（GGT） between the two groups（P〈0.05）. After treatment, ALT（45.31 IU/L ± 10.04 IU/L vs 68.42 IU/L ± 11.46 IU/L） and GGT（41.46 IU/L ± 10.24 IU/L vs 52.17 IU/L ± 11.25 IU/L） were significantly lower in the observation group than in the control group（P〈0.05）. There was no significantly difference in the rate of adverse effects between the two groups（P〈0.05）.CONCLUSION Traditional Chinese medicine decoction combined with Western medicine symptomatic support can improve the liver function of elderly autoimmune liver disease patients with gastritis, without increasing the rate of adverse effects.